Fei Wu

3.3k total citations · 1 hit paper
106 papers, 2.2k citations indexed

About

Fei Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Fei Wu has authored 106 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 24 papers in Pulmonary and Respiratory Medicine and 23 papers in Oncology. Recurrent topics in Fei Wu's work include Ubiquitin and proteasome pathways (8 papers), Epigenetics and DNA Methylation (8 papers) and Prostate Cancer Treatment and Research (8 papers). Fei Wu is often cited by papers focused on Ubiquitin and proteasome pathways (8 papers), Epigenetics and DNA Methylation (8 papers) and Prostate Cancer Treatment and Research (8 papers). Fei Wu collaborates with scholars based in China, United States and Hong Kong. Fei Wu's co-authors include Jinfang Zhang, Wenyi Wei, Jianping Guo, Xiangpeng Dai, Yan Geng, Piotr Siciński, Yuyong Tan, Yanpeng Ci, Yinghao Sun and Gordon J. Freeman and has published in prestigious journals such as Nature, Blood and Molecular Cell.

In The Last Decade

Fei Wu

92 papers receiving 2.2k citations

Hit Papers

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP... 2017 2026 2020 2023 2017 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Wu China 23 1.1k 815 487 433 343 106 2.2k
Gerold Untergasser Austria 29 1.1k 1.0× 527 0.6× 411 0.8× 280 0.6× 370 1.1× 84 2.4k
Baoqing Jia China 29 1.4k 1.3× 632 0.8× 292 0.6× 328 0.8× 731 2.1× 87 2.5k
Jean‐Christophe Stehle Switzerland 25 1.7k 1.5× 660 0.8× 655 1.3× 447 1.0× 543 1.6× 27 2.7k
Anna Biernacka United States 21 1.5k 1.4× 586 0.7× 490 1.0× 181 0.4× 270 0.8× 40 2.8k
Michaela Schlederer Austria 21 892 0.8× 767 0.9× 244 0.5× 289 0.7× 323 0.9× 40 1.9k
Damien Ambrosetti France 26 867 0.8× 489 0.6× 574 1.2× 199 0.5× 368 1.1× 90 2.3k
Douglas W. Strand United States 27 1.0k 0.9× 529 0.6× 835 1.7× 256 0.6× 501 1.5× 73 2.4k
Zhongwei Cao China 26 1.6k 1.4× 514 0.6× 589 1.2× 326 0.8× 713 2.1× 43 3.0k
Keiji Hirata Japan 28 1.2k 1.0× 1.1k 1.3× 402 0.8× 268 0.6× 333 1.0× 189 2.8k
Shohei Shimajiri Japan 29 752 0.7× 479 0.6× 610 1.3× 465 1.1× 269 0.8× 113 2.3k

Countries citing papers authored by Fei Wu

Since Specialization
Citations

This map shows the geographic impact of Fei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Wu more than expected).

Fields of papers citing papers by Fei Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Wu. The network helps show where Fei Wu may publish in the future.

Co-authorship network of co-authors of Fei Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Wu. A scholar is included among the top collaborators of Fei Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Wu. Fei Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Amin, Nashwa, Qing Ye, Shijia Chen, et al.. (2025). Combination of rTMS and oxytocin agonist attenuate depression-like behavior after postpartum depression in mice. Brain Research. 1851. 149459–149459.
2.
Zhu, Wen, Fei Wu, Zhongdong Qiao, Ming Zhao, & Haiyang Hu. (2025). Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy. Theranostics. 15(11). 5007–5028. 1 indexed citations
3.
Kang, Xiaoyu, Lin Zhang, Shushang Liu, et al.. (2025). Platinum drugs upregulate CXCR4 and PDL1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer. The Journal of Pathology Clinical Research. 11(1). e70015–e70015. 1 indexed citations
4.
Xie, Yubin, Chen Chen, Fei Wu, et al.. (2025). Single‐Cell Analysis Clarifies Pathological Heterogeneity in Tenosynovial Giant Cell Tumor and Identifies Biomarkers for Predicting Disease Recurrence. Advanced Science. 12(26). e2415835–e2415835. 1 indexed citations
5.
Xue, Sun, et al.. (2025). Difficulties and needs of new nurse managers during role transition: A perspective from role theory. International Nursing Review. 72(1). e70011–e70011.
6.
Wang, Ting, Chunli Zhang, Yanping Ding, et al.. (2024). BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma. Journal for ImmunoTherapy of Cancer. 12(9). e009476–e009476. 4 indexed citations
7.
Li, Chaofan, Chen Feng, Shiyu Sun, et al.. (2024). Prognostic prediction for inflammatory breast cancer patients using random survival forest modeling. Translational Oncology. 52. 102246–102246. 3 indexed citations
8.
Wu, Fei, et al.. (2024). Thyrotropin induces atherosclerosis by upregulating large conductance Ca2+-activated K+ channel subunits. Molecular and Cellular Endocrinology. 583. 112145–112145.
9.
11.
Gu, Yong, Yajing Cao, Yan Zhao, et al.. (2023). Successful treatment of hidradenocarcinoma using ALA-PDT combined with local narrow margin excision. Photodiagnosis and Photodynamic Therapy. 44. 103791–103791. 1 indexed citations
12.
Wu, Fei, Changyan Xiao, Xiaozheng Chen, et al.. (2023). Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer. Experimental Hematology and Oncology. 12(1). 67–67. 26 indexed citations
13.
Wu, Fei, et al.. (2022). Semaphorin 3D inhibits proliferation and migration of papillary thyroid carcinoma by regulating MAPK/ERK signaling pathway. Molecular Biology Reports. 49(5). 3793–3802. 5 indexed citations
14.
Yue, Peng, Yu Wang, Fei Wu, & Yongjie Chen. (2022). Association of cooking fuel with incident hypertension among adults in China: A population‐based cohort study. Journal of Clinical Hypertension. 24(8). 1003–1011. 7 indexed citations
15.
Liang, Peir‐In, Fei Wu, Yi Chu, et al.. (2021). Metabolic derangement in polycystic kidney disease mouse models is ameliorated by mitochondrial-targeted antioxidants. Communications Biology. 4(1). 1200–1200. 21 indexed citations
16.
Cao, Chenxi, Fei Wu, Xiaoqing Hu, et al.. (2020). Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis. Theranostics. 10(23). 10573–10588. 34 indexed citations
17.
Ding, Qiang, Fei Wu, Shanhua Mao, et al.. (2017). Aldosterone induces inflammatory cytokines in penile corpus cavernosum by activating the NF-κB pathway. Asian Journal of Andrology. 20(1). 24–24. 7 indexed citations
18.
Wu, Fei, et al.. (2016). Irisin is Associated with Urotensin II and Protein Energy Wasting in Hemodialysis Patients. Kidney & Blood Pressure Research. 41(1). 78–85. 17 indexed citations
19.
Sun, Liang, Jiajü Lü, Zhihong Niu, et al.. (2015). A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer. PLoS ONE. 10(12). e0144484–e0144484. 29 indexed citations
20.
Wu, Fei, Lili Guo, Aniela Jakubowski, et al.. (2013). TNF-Like Weak Inducer of Apoptosis (TWEAK) Promotes Beta Cell Neogenesis from Pancreatic Ductal Epithelium in Adult Mice. PLoS ONE. 8(8). e72132–e72132. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026